Canaccord analyst John Newman lowered the firm’s price target on Atreca to $8 from $20 and keeps a Buy rating on the shares. The analyst said his lower price target reflects decreased total market assumptions, as we believe the combination arm versus monotherapy arm may be the best opportunity for ATRC-101.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BCEL:
- Atreca downgraded to In Line from Outperform at Evercore ISI
- Atreca: Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year
- Atreca reports Q4 EPS (55c), consensus (59c)
- Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update
- Atreca (BCEL) Q4 Earnings Cheat Sheet
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue